Please assess the completion status of the following clinical trial:

Trial Title: Combined Patching-Atropine for Residual Amblyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 to \< 10 years~* Amblyopia associated with strabismus, anisometropia, or both~* Visual acuity in the amblyopic eye between 20/32 and 20/63 inclusive~* Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>= 2 logMAR lines~* Current/previous treatment with patching and/or atropine subject to the following stipulations:~  * No simultaneous treatment with patching and atropine in the past 6 months~ * No prior use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D~ * Maximum level of any previous treatment:~    * Patching: up to 42 hours per week (averaging 6 hours daily)~   * Atropine: up to once daily~ * Current treatment with 42 hours per week patching or daily atropine~* No improvement in best-corrected amblyopic eye visual acuity between two consecutive visits at least 6 weeks apart using the same testing method and optimal spectacle correction (if needed), with no improvement defined as follows:~  * No lines of improvement~ * For patients tested using E-ETDRS, letter score that is no more than 4 letters improved~* Wearing spectacles with optimal correction (if applicable)~* Investigator ready to wean or stop treatment~Exclusion Criteria:~* Current vision therapy or orthoptics~* Ocular cause for reduced visual acuity~* Prior intraocular or refractive surgery~* Strabismus surgery planned within 10 weeks~* Known allergy to atropine or other cycloplegic drugs~* Known skin reactions to patch or bandage adhesives~* Down Syndrome present

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Intensive (Type: ACTIVE_COMPARATOR): 42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
- Weaning (Type: ACTIVE_COMPARATOR): For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)

Based on this trial design, predict the completion outcome and termination type (if applicable).